{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-005486","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.998414+00:00","generated_at":"2026-05-16T11:23:22.010599+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet Bio reports prula-cel Phase 1 enrollment doubles to 20+ patients; FDA allows outpatient dosing for SLE/LN","bullets":["Enrollment in prula-cel autoimmune Phase 1 program doubled to over 20 patients as of Dec 31, 2025.","FDA alignment achieved to allow outpatient dosing of SLE and lupus nephritis patients in ongoing and future trials.","Plans to request FDA meeting in Q2 2026 to discuss potential Phase 2 pivotal trial design for prula-cel.","Regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer expected in H1 2026.","Cash runway extended into H2 2027 following $74.8M net proceeds from October 2025 equity offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-005486","json":"https://secwatch.observer/filing/0001193125-26-005486.json","markdown":"https://secwatch.observer/filing/0001193125-26-005486.md","text":"https://secwatch.observer/filing/0001193125-26-005486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/0001193125-26-005486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/acet-20260107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:23:22.010599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}